New drugs developed to inhibit TLR4 activity are already in various phases of preclinical and clinical trials for treating acute and chronic inflammation, colitis, sepsis, chronic pain, and addiction withdrawal [12,17,18,19,20,21]. The gene discussed is TLR4; the disease is colitis.